Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Femipause is an oral over-the-counter menopause support dietary supplement marketed by PharmaS for relief of menopausal symptoms. It is presented as a dual day and night capsule regimen, with the day formula containing red clover extract standardized to provide isoflavones, flaxseed extract with lignans, and B vitamins, and the night formula containing melatonin. Its intended use is symptomatic support for vasomotor and sleep-related menopausal complaints such as hot flashes, night sweats, palpitations, fatigue, and sleep disturbance. The product appears to act through a combination of phytoestrogenic support from red clover and flax-derived lignans together with sleep-promoting chronobiologic support from melatonin, rather than through a single well-defined pharmaceutical target-mechanism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Femipause.